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However, we focused on mechanisms that directly account for increased intestinal apolipoprotein B production by PCSK9 and showed for the first time that mRNA levels of proteins (FAS, SCD, and DGAT2) involved in chylomicron assembly are increased by the addition of exogenous PCSK9 to CaCo-2 cells, that these effects are low-density lipoprotein receptor dependent, and that they are reversed by acute siRNA silencing of PCSK9 gene expression. 1 Because we placed no emphasis on NPC1L1, we felt that not mentioning the article by Levy et al was appropriate given the space limitations. Le May and Cariou then ask whether in our study exogenous PCSK9 was added at the apical or basolateral side of CaCo-2 cells. We presented data from PCSK9 added to the apical side but obtained similar results after adding it to the basolateral side. This is in line with previous work in which Levy et al 4 show that CaCo-2 cells secrete PCSK9 mostly into the basolateral medium, whereas Le May et al 2 state that enterocytes show "strong PCSK9 immunostaining mainly in the apical compartment" and that "PCSK9…accumulates at the subapical and basolateral compartments of the enterocyte."
Finally, Le May and Cariou question our claim of having used a physiological dose of PCSK9 in the studies of Caco-2 cells 1 and suggest instead that the dose we chose is 2-to 3-fold higher than the highest physiological human PCSK9 concentration. We disagree with this statement because 10 μg/mL, the concentration we used to stimulate CaCo-2 cells, mimics the physiological effect of PCSK9 in vitro and is at the high end of the physiological PCSK9 concentration in humans.
